Table 1.

Frequency of TERT promoter mutations

Tumor type*No. tumorsNo. tumors mutated (%)
Chondrosarcoma21 (50)
Dysembryoplastic neuroepithelial tumor31 (33.3)
Endometrial cancer192 (10.5)
Ependymoma361 (2.7)
Fibrosarcoma31 (33.3)
Glioma223114 (51.1)
Hepatocellular carcinoma6127 (44.2)
Medulloblastoma9119 (20.8)
Myxofibrosarcoma101 (10.0)
Myxoid liposarcoma2419 (79.1)
Neuroblastoma222 (9)
Osteosarcoma231 (4.3)
Ovarian, clear cell carcinoma122 (16.6)
Ovarian, low grade serous81 (12.5)
Solitary fibrous tumor (SFT)102 (20.0)
Squamous cell carcinoma of head and neck7012 (17.1)
Squamous cell carcinoma of the cervix221 (4.5)
Squamous cell carcinoma of the skin51 (20)
Urothelial carcinoma of bladder2114 (66.6)
Urothelial carcinoma of upper urinary epithelium199 (47.3)
  • * No mutations were found in acute myeloid leukemia (n = 48), alveolar rhabdomyosarcoma (n = 7), atypical lipomatous tumor (n = 10), breast carcinoma (n = 88), cholangiosarcoma (n = 28), central/conventional chondrosarcoma (n = 9), chronic lympoid leukemia (n = 15), chronic myeloid leukemia (n = 6), colorectal adenocarcinoma (n = 22), embryonal rhabdomyosarcoma (n = 8), esthesioneuroblastoma (n = 11), extraskeletal myxoid chondrosarcoma (n = 3), fibrolammellar carcinoma of the liver (n = 12), gall bladder carcinoma (n = 10), gastrointestinal stromal tumor (n = 9), hepatoblastoma (n = 3), leiomyosarcoma (n = 3), conventional lipoma (n = 8), low grade fibromyxoid sarcoma (n = 9), malignant peripheral nerve sheath tumor (n = 3), medullary thyroid carcinoma (n = 24), meningioma (n = 20), mesothelioma (n = 4), pancreatic acinar carcinoma (n = 25), pancreatic ductal adenocarcinoma (n = 24), pancreatic neuroendocrine tumor (n = 68), prostate carcinoma (n = 34), spinal ependymoma (n = 9), synovial sarcoma (n = 16), or undifferentiated pleomorphic soft tissue sarcoma (n = 10) samples.

  • Glioma comprises 11 subtypes; see Dataset S1 and Table S3.